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Abstract  
Background and purpose: Recent genome-wide association
studies have indicated 3 new susceptibility loci for Alzheimer
disease (AD): complement receptor 1 (CR1), clusterin (CLU),
and the phosphatidylinositol-binding clathrin assembly 
protein (PICALM). We investigated the influence of the
rs6656401 single nucleotide polymorphisms (SNP) of the
CR1 gene, the rs3851179 SNP of the PICALM gene, and
the rs11136000 SNP of the CLU gene on risk of AD in a Po -
lish population.
Material and methods: In 253 Caucasian AD patients and
240 controls, analyses identifying the rs6656401, rs3851179
and rs11136000 SNPs and APOE common polymorphisms
were performed. 
Results: No significant differences were observed in the dis-
tribution of the rs6656401 of CR1, rs3851179 of PICALM
and rs11136000 of CLU SNPs between AD patients and con-
trols. The APOE ε4 common polymorphism was strongly re -
lated to the risk of AD. 
Conclusion: Our results suggest that investigated SNPs are
not associated with AD in a Polish population.
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SHORT REPORT/KRÓTKIE DONIESIENIE
St reszc zen ie
Wstêp i cel pracy: Metod¹ przeszukiwania genomu ludzkiego
(genome-wide associations study – GWAS) stwierdzono zwi¹zek
pomiêdzy sporadyczn¹ postaci¹ choroby Alzheimera a genem
koduj¹cym g³ówny receptor dla sk³adowej C3b dope³niacza
(CR1), intronem genu dla klasteryny (CLU) oraz genem
bia³ka b³on synaptycznych (PICALM). Celem obecnego
badania by³a ocena wp³ywu wybranych polimorfizmów:
rs6656401 genu CR1, rs3851179 genu PICALM oraz
rs11136000 genu CLU na ryzyko rozwoju choroby Alzhei -
mera w polskiej populacji.
Materia³ i metody: W badaniu oznaczono polimorfizm
rs6656401 genu CR1, rs3851179 genu PICALM oraz
rs11136000 genu CLU, a tak¿e apolipoproteiny E (APOE)
u 253 osób ze sporadyczn¹ postaci¹ choroby Alzheimera i 240
osób z grupy kontrolnej. 
Wyniki: Rozk³ad wybranych polimorfizmów u osób z cho-
rob¹ Alzheimera i w grupie kontrolnej by³ podobny. Badanie
potwierdzi³o, ¿e APOE ε4 jest czynnikiem ryzyka rozwoju
choroby Alzheimera. 
Wniosek: Polimorfizmy rs6656401, rs3851179, rs11136000
nie s¹ czynnikami ryzyka wyst¹pienia choroby Alzheimera
o póŸ nym pocz¹tku w populacji polskiej. 
S³owa kluczowe: choroba Alzheimera, CR1, PICALM, CLU,
polimorfizm pojedynczego nukleotydu.
Correspondence address: Aleksandra Klimkowicz-Mrowiec, MD, PhD, Department of Neurology, University Hospital, Jagiellonian University College 
of Medicine, Botaniczna 3, 31-503 Krakow, Poland, phone: +48 12 424 86 00, fax: +48 12 424 86 26, e-mail: Aleksandra.Klimkowicz@mp.pl
Received: 17.03.2012; accepted: 1.08.2012
Neurologia i Neurochirurgia Polska 2013; 47, 2158
Introduction
Mutations in the amyloid precursor proteins prese-
nilin-1 and -2 account for most cases of early onset Alzhei -
mer disease (AD) but only for 1-5% of all AD cases. 
The late onset form of the disease (LOAD) is poorly
defined genetically, and until recently the only known risk
factor was the ε4 allele of APOE. Because it is estimated
that APOE may account for up to 50% of AD genetic
susceptibility [1], other genetic factors must play a role in
pathogenesis or protective mechanisms of AD.
So far, more than six hundred genes have been inves-
tigated as susceptibility factors for LOAD. Recently
published genome-wide associations studies identified
three new potential loci for AD: complement receptor 1
(CR1), clusterin (CLU), and the phosphatidylinositol-
binding clathrin assembly protein (PICALM). 
The protein products of these genes might influence
β-amyloid clearance and thus influence the accumula-
tion of amyloid pathology by preventing amyloid plaque
formation [2,3].
In the present study we investigated the CR1
rs6656401, CLU rs3851179 and PICALM rs11136000
single nucleotide polymorphisms (SNPs) and APOE
common polymorphisms that were shown previously to
affect the risk of AD in different populations in a sam-
ple of Polish patients with LOAD and compared them
with a group of non-demented controls.
Material and methods
Subjects 
The consecutive patients, without a family history of
AD, were recruited from the Outpatient Memory Clin-
ic, Neurology Department, University Hospital in Kra -
kow. The clinical diagnosis of probable AD was made
according to the National Institute for Neurological and
Communicative Disorders and Stroke and the Alz hei -
mer’s Disease and Related Disorders Association crite-
ria [4]. Onset of AD was defined as the age at which
me mory loss or change in behavior was first noted. 
The evaluation included medical, neurological and neu-
ropsychological examination, interview with a close
informant, laboratory testing and computed tomogra-
phy or magnetic resonance imaging. The details of
patient’s evaluation are described elsewhere [5].
The patients from the control group were consecu-
tively recruited from the population of Krakow. They
had no apparent neurological or psychiatric disease, cere-
brovascular disease, or any functional limitations and
obtained > 26 points on the Mini-Mental State Exa -
mination (MMSE) [6]. Controls and AD patients were
Caucasian and of Eastern European descent. 
All participants gave informed consent and the study
was approved by the Local Ethical Committee.
DNA analyses
The CR1 rs6656401, CLU rs3851179 and PICALM
rs11136000 SNPs and the APOE common polymor-
phism were studied. DNA was extracted from leuko-
cytes using the standard protocol. The individual geno-
types for rs6656401, rs3851179 and rs11136000 SNPs
were determined using the polymerase chain reaction
restriction fragment length polymorphism method. 
Real-time PCR was performed using a protocol pro-
vided by Applied Biosystems to assess CR1 rs6656401,
CLU rs3851179 and PICALM rs11136000 polymor-
phisms.
To determine the APOE genotype (APOE ε2,
APOE ε3, APOE ε4 alleles), we genotyped two single-
nucleotide polymorphisms (SNPs; NCBI SNPs
rs429358 and rs7412) using TaqMan assays (Applied
Biosystems [ABI], Foster City, CA).
Statistical analyses 
Demographic data between groups were compared
by χ2 (gender) or t-test (age).
The genotype and allele frequencies of the CR1,
CLU, PICALM SNPs were compared between cases
and controls using the χ2 test (SAS Genetics 9.1). For
non-normally distributed variables differences among
the groups were tested by Mann-Whitney U-test. 
The Hardy-Weinberg equilibrium was verified for all
polymorphisms in the tested population. The level of
significance was set at p < 0.05. 
Results
We studied a total sample of 493 subjects. The AD
group consisted of 253 patients (mean age: 73.9 ± 5.2
years, 173 females [68.4%]). The control group includ-
ed 240 unrelated caregivers or volunteers (mean age:
73.8 ± 6.9 years; 138 females [57.5%]). There was no
difference in age between the two groups. The groups
differed significantly regarding gender (p = 0.01).
APOE ε4 was strongly related to the risk of AD (OR =
6.17; CI: 4.01-9.49).
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Association of CR1, PICALM and CLU gene polymorphisms with AD
We did not find a significant difference of three stud-
ied polymorphisms between the populations. Table 1
shows the details. 
Discussion
We studied 3 different SNPs of genes which encode
proteins potentially involved in pathophysiology of AD
[7]. Clusterin, also called apolipoprotein J, is a protein
involved in membrane recycling and apoptosis. Clus-
terin binds in a specific and reversible manner with sol-
uble β-amyloid and forms complexes that cross the
blood-brain barrier [8]. Clusterin was also found in
amyloid plaques [9]. The gene encoding clusterin, CLU
(chromosome 8), was investigated as a susceptibility fac-
tor for LOAD in genome-wide association studies and
candidate gene studies. Meta-analytic data showed that
clusterin rs11136000 SNP is associated with LOAD in
Caucasian subjects [7].
Phosphatidylinositol-binding clathrin assembly pro-
tein is a key component of clathrin-mediated endocyto-
sis. AD brains show a reduced number of synapses.
PICALM is involved in a process that is crucial to the
functional integrity of synapses. PICALM could pro-
mote the synthesis of β-amyloid by regulating endocy-
tosis of endocytic compartments with amyloid precursor
protein [10]. The PICALM rs 11136000 SNP (chro-
mosome 11) was found to be associated with LOAD in
Caucasians [7]. 
CR1 is a receptor for the complement fragments
C3b and C4b and is expressed on many different cell
types, particularly in the circulatory system. The com-
plement inhibition was shown to reduce the clearance of
β-amyloid in animal models [11]. CR1 is also involved
in clearance of peripheral blood β-amyloid from the
bloodstream. Meta-analytic data showed the association
between CR1 rs3818361 and LOAD in Caucasians [7].
Although most published studies have found an as -
sociation between the three studied polymorphisms and
AD, we did not find such an association in a Polish po -
pulation in the present study. 
Conclusions
AD is most likely a multifactorial condition, which
involves a combination of genetic, lifestyle, and envi-
ronmental factors. The influence of investigated poly-
morphisms is probably weak and a very large population
is needed to reveal the association. Even though the pre-
sent study does not confirm the association between the
assessed polymorphisms and AD risk in Caucasians, it
can be considered valuable as our data can be used for
future meta-analyses and help to establish more precisely
the role of SNPs in the pathogenesis of AD.
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